The lifetime risk of developing ovarian cancer in individuals with Lynch syndrome has been reported to be approximately 11.0% (7.4–19.7) for MLH1, 17.4% (11.8–31.2) for MSH2, 10.8% (3.7–38.6) for MSH6, and 3.0% (0.5–43.3) for PMS2 pathogenic variant carriers [148]. Here, MLH1 is linked to Lynch syndrome.